Evidence map›Paper›PMID 30642127›Full record

ReviewMolecules (Basel, Switzerland)2019

Biochemical Basis of Anti-Cancer-Effects of Phloretin-A Natural Dihydrochalcone.

Bu Young Choi

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Via Air or Rhizosphere: The Phytotoxicity ofPlants (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Antibacterial Activity of Phloretin AgainstFoods (Basel, Switzerland) · 2024
    Article
  9. Review
  10. Inhibition of NAMPT by PAK4 Inhibitors.International journal of molecular sciences · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Bu Young ChoiDepartment of Pharmaceutical Science & Engineering, Seowon University, Cheongju, Chungbuk 361-742, Korea. bychoi@seowon.ac.kr.ORCID 0000-0001-8698-5880
Seowon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apple is a rich source of bioactive phytochemicals that help improve health by preventing and/or curing many disease processes, including cancer. One of the apple polyphenols is phloretin [2',4',6'-Trihydroxy-3-(4-hydroxyphenyl)-propiophenone], which has been widely investigated for its antioxidant, anti-inflammatory and anti-cancer activities in a wide array of preclinical studies. The efficacy of phloretin in suppressing xenograft tumor growth in athymic nude mice implanted with a variety of human cancer cells, and the ability of the compound to interfere with cancer cells signaling, have made it a promising candidate for anti-cancer drug development. Mechanistically, phloretin has been reported to arrest the growth of tumor cells by blocking cyclins and cyclin-dependent kinases and induce apoptosis by activating mitochondria-mediated cell death. The blockade of the glycolytic pathway via downregulation of GLUT2 mRNA and proteins, and the inhibition of tumor cells migration, also corroborates the anti-cancer effects of phloretin. This review sheds light on the molecular targets of phloretin as a potential anti-cancer and anti-inflammatory natural agent.

Indexed as

AnimalsAnti-Inflammatory AgentsAntineoplastic AgentsChalconesHumansModels, AnimalPhloretinAnti-Inflammatory AgentsAntineoplastic AgentsChalconesdihydrochalconePhloretinapoptosiscell proliferationglucose uptakeinflammationmigrationphloretin

Identifiers

PMID30642127
PMCPMC6359539
OpenAlexW2910273753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.